<DOC>
	<DOCNO>NCT00338494</DOCNO>
	<brief_summary>Clofarabine new chemotherapy drug FDA approve treatment acute lymphocytic leukemia child . This study do see Clofarabine work adult patient B-cell type lymphoma . This research do develop new treatment patient lymphoma whose cancer return resist treatment previous chemotherapy .</brief_summary>
	<brief_title>Dose Escalation Study Clofarabine Patients With Relapsed Refractory Low Grade Intermediate-Grade B-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>Adult patient least 18 year old Histologically confirm low grade intermediategrade Bcell lymphoma Relapsed refractory least one standard chemotherapy regimen . Patients receive Rituximab alone without receive cytotoxic agent eligible . Measurable disease , define Cheson lymphoma criterion . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Life expectancy great 12 week Laboratory value obtain ≤2 week prior entry Absolute neutrophil count ( ANC ) ≥ 1000 x 10 9/L White blood cell ( WBC ) count &gt; 2.5 x 10 9/L Platelets ≥ 75 x 10 9/L Hemoglobin ( Hg ) &gt; 9.0 g/dL Total bilirubin ≤2.0 mg/dL Aspartate transaminase ( AST ) /alanine transaminase ( ALT ) ≤3 × upper limit normal ( ULN ) Serum creatinine ≤2.0 mg/dL Normal cardiac function , define ejection fraction ≥45 % determined pretreatment radionuclide ventriculography ( RVG ) echocardiogram . Capable understanding investigational nature , potential risk benefit study , able provide valid inform consent . Female patient childbearing potential must negative serum pregnancy test within 2 week prior enrollment . Male female patient must use effective contraceptive method study minimum 6 month study treatment . Previously untreated Bcell lymphoma . Received previous treatment clofarabine . Patients know AIDSrelated HIVpositive lymphoma . Autologous bone marrow stem cell transplant within 6 month study entry . Prior radiotherapy site measurable disease . Any medical condition require chronic use oral highdose corticosteroid great 20 mg/day prednisone . Active autoimmune thrombocytopenia . Use investigational agent within 30 day anticancer therapy within 3 week study entry . The patient must recover acute toxicity previous therapy . Patients active , uncontrolled systemic infection consider opportunistic , life threatening , clinically significant time treatment know suspected fungal infection ( ie , patient parenteral antifungal therapy ) . Active secondary malignancy . Pregnant lactating patient . Any significant concurrent disease , illness , psychiatric disorder would compromise patient safety compliance , interfere consent , study participation , follow , interpretation study result . Patients active untreated central nervous system ( CNS ) lymphoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>